Veradermics, Inc
Business
Veradermics is a late-stage biopharmaceutical company developing innovative therapeutics for aesthetic and dermatological conditions, with initial focus on treating pattern hair loss affecting approximately 80 million Americans. The company's lead candidate, VDPHL01, is an oral extended-release formulation of minoxidil designed to maximize hair growth while minimizing cardiac risk, offering the first non-hormonal oral treatment option for both men and women. VDPHL01 is in registration-directed Phase 2/3 and Phase 3 clinical trials, with topline data anticipated in 2026, supported by a comprehensive commercialization strategy targeting dermatology practices and direct-to-consumer channels in the U.S. market.
Summary from 10-K filed 2026-03-30
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Research and development | 62 | 23 | |
| General and administrative | 10 | 3 | |
| Total operating expenses | 72 | 27 | |
| Loss from operations | −72 | −27 | |
| Interest income | 2 | 481,000 | |
| Other income | 790,000 | 394,000 | |
| Interest expense | 0 | −585,000 | |
| Total other income, net | 2 | 290,000 | |
| Loss before income taxes | −70 | −26 | |
| Income tax benefit | 0 | 0 | |
| Net loss | −70 | −27 | |
| Net loss attributable to common stock, basic | −83 | −27 | |
| Net loss attributable to common stock, diluted | −83 | −27 | |
| Net loss per share of common stock, basic (in usd per share) | −111.91 | −37.05 | |
| Net loss per share of common stock, diluted (in usd per share) | −111.91 | −37.05 | |
| Weighted average common stock outstanding, basic (in shares) | 744,991 | 736,933 | |
| Weighted average common stock outstanding, diluted (in shares) | 744,991 | 736,933 | |
| Net unrealized gains on marketable securities | 60,000 | 0 | |
| Total other comprehensive income | 60,000 | 0 | |
| Total comprehensive loss | −70 | −26 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | 22 | 53 | — | |
| Marketable securities at fair value | 120 | 0 | — | |
| Prepaid expenses and other current assets | 11 | 2 | — | |
| Total current assets | 152 | 56 | — | |
| Property, plant and equipment, net | 22,000 | 0 | — | |
| Right-of-use asset and other long-term assets | 100,000 | 0 | — | |
| Total non-current assets | 125,000 | 0 | — | |
| Total assets | 153 | 56 | — | |
| Accounts payable | 2 | 2 | — | |
| Accrued expenses | 7 | 2 | — | |
| Other current liabilities and lease liabilities | 47,000 | 0 | — | |
| Total current liabilities | 9 | 5 | — | |
| Lease liabilities - non-current | 4,000 | 0 | — | |
| Total liabilities | 9 | 5 | — | |
| Commitments and contingencies (Note 10) | — | — | — | |
| Subscription receivable | −2 | −4 | −894,000 | |
| Common stock, $0.00001 par value, 98,774,582 and 25,500,000 authorized as of December 31, 2024 and 2023, respectively and 7,418,740 shares issued and outstanding | 1,000 | 1,000 | — | |
| Additional paid-in capital | 2 | 750,000 | — | |
| Accumulated other comprehensive income | 60,000 | 0 | — | |
| Accumulated deficit | −123 | −49 | — | |
| Total stockholders deficit | −121 | −48 | −22 | |
| Total liabilities, redeemable convertible preferred stock, and stockholders deficit | 153 | 56 | — |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 |
|---|---|---|---|
| Stock-based compensation | 1 | 250,000 | |
| Research and development expenses paid with convertible and promissory notes | 0 | 234,000 | |
| Non-cash research and development services | 2 | 1 | |
| Net accretion of discount/premium on debt securities | −556,000 | 0 | |
| Accrued interest earned | −647,000 | 0 | |
| Other | 43,000 | 573,000 | |
| Prepaid expenses and other current assets | −8 | −1 | |
| Accounts payable | −122,000 | 646,000 | |
| Accrued expenses | 5 | 1 | |
| Other current liabilities and lease liabilities | −39,000 | 0 | |
| Net cash used in operating activities | −72 | −24 | |
| Purchase of property, plant and equipment | −24,000 | 0 | |
| Purchases of marketable securities | −144 | 0 | |
| Maturities of marketable securities | 25 | 0 | |
| Net cash used in investing activities | −119 | 0 | |
| Issuance of convertible notes | 0 | 9 | |
| Payment of promissory note | 0 | −845,000 | |
| Exercise of stock options | 156,000 | 0 | |
| Net cash provided by financing activities | 159 | 60 | |
| Net increase (decrease) in cash and cash equivalents | −31 | 37 | |
| Cash paid during the year for interest | 0 | 95,000 | |
| Cash paid during the year for income taxes | 0 | 0 | |
| Right-of-use asset exchanged for lease liabilities | 90,000 | 0 | |
| Unrealized gain on debt securities | 60,000 | 0 | |
| Issuance of Series B preferred stock for contractual research and development services | 0 | 3 | |
| Issuance of Series B preferred stock as payment for convertible notes | 0 | 10 | |
| Issuance of convertible note for research and development services | 0 | 1 | |
| Conversion of other receivable in exchange for research and development services to subscription receivable | 0 | 932,000 | |
| Issuance of convertible note for accounts payable | 0 | 250,000 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is Veradermics, Inc's CIK number?
Veradermics, Inc's SEC CIK number is 0001827635 (1827635). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Veradermics, Inc's SEC filings?
All of Veradermics, Inc's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did Veradermics, Inc last report earnings?
Veradermics, Inc (MANE) most recently filed an earnings 8-K with the SEC on May 12, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001827635-26-000016). This is Veradermics, Inc's most recent earnings filing of record — not a forecast of its next earnings date.
What is Veradermics, Inc's most recent earnings 8-K?
Veradermics, Inc's latest earnings 8-K (Item 2.02) was filed May 12, 2026 under accession 0001827635-26-000016. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View Veradermics, Inc's latest earnings 8-K →
Look up any company's CIK number →